Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Zhang, Ju Bo ^a   Sun, Hui Chuan ^a   Jia, Wei Dong ^a,b   Zhuang, Peng Yuan ^a   Qian, Yong Bing ^a   Zhu, Xiao Dong ^a   Kong, Ling Qun ^a   Wang, Lu ^a   Wu, Wei Zhong ^a   Tang, Zhao You ^a  

^a FUDAN UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Interferon ; Microvessel density; Platelet derived growth factor A; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; IMATINIB; PLATELET DERIVED GROWTH FACTOR A; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA1B INTERFERON; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CARCINOMA CELL; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; LIVER CELL CARCINOMA; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BLOOD LEVEL; RETREATMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TUMOR VASCULARIZATION; UPREGULATION; VASCULOTROPIN BLOOD LEVEL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RETREATMENT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT FAILURE; TUMOR BURDEN; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866777224     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-439     Document Type: Article

References (47)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v2.0, cancer incidence and mortality worldwide: IARC CancerBase No. 10 (Internet) 2010, International Agency for Research on Cancer, Lyon, Available from: http://globocan.iarc.fr, accessed on day/month/year.
2. Sun HC, Tang ZY. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 2004, 130:307-319. 10.1007/s00432-003-0530-y, 15034787.
3. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6:273-286. 10.1038/nrd2115, 17396134.
4. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611. 10.1210/er.2003-0027, 15294883.
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676. 10.1038/nm0603-669, 12778165.
6. Guangqi E, Cao Y, Bhattacharya S, et al. Endogenous vascular endothelial growth factor-A (VEGF-A) maintains endothelial cell homeostasis by regulating VEGF receptor-2 transcription. J Biol Chem 2012, 287:3029-3041. 10.1074/jbc.M111.293985, 22167188.
7. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371. 10.1038/nrm1911, 16633338.
8. Doi Y, Yashiro M, Yamada N, et al. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. Ann Surg Oncol 2012, 19:2733-2743. 10.1245/s10434-011-2181-6, 22207048.
9. Vacca A, Ria R, Ribatti D, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003, 88:176-185.
10. Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004, 56:549-580. 10.1124/pr.56.4.3, 15602010.
11. von Marschall Z, Scholz A, Cramer T, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003, 95:437-448. 10.1093/jnci/95.6.437, 12644537.
12. Wang L, Tang ZY, Qin LX, et al. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 2000, 32:43-48.
13. Folkman JMJ, Ezekowitz RAB. Antiangiogenic therapy of haemangiomas with interferon A. The clinical applications of the interferons 1997, 255-265. Chapman & Hall Medical, London, England, Stuart-Harris R, Penny R.
14. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003, 21:421-427. 10.1200/JCO.2003.10.103, 12560429.
15. Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006, 106:1990-1997. 10.1002/cncr.21832, 16565970.
16. Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006, 132:458-465. 10.1007/s00432-006-0091-y, 16557381.
17. Ravaud A, Dilhuydy MS. Interferon alpha for the treatment of advanced renal cancer. Expert Opin Biol Ther 2005, 5:749-762. 10.1517/14712598.5.6.749, 15952906.
18. DiPaola RS, Rafi MM, Vyas V, et al. Phase I clinical andpharmacologic study of 13-cis-retinoicacid, interferon alfa, and paclitaxel in patientswith prostate cancer andother advanced malignancies. J Clin Oncol 1999, 17:2213-2218.
19. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354:709-718. 10.1056/NEJMoa053007, 16481638.
20. Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control 2002, 9:16-21.
21. Agarwala SS, Kirkwood JM. Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Williston Park) 2002, 16:1177-87. discussion 1190-1192, 1197.
22. Krauze MT, Tarhini A, Gogas H, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol 2011, 33:385-391. 10.1007/s00281-011-0247-y, 21279809.
23. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007, 89:884-893. 10.1016/j.biochi.2007.04.006, 17532550.
24. Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000, 106:705-714. 10.1172/JCI10196, 381287, 10974024.
25. Fujii S. Role of interferon-alpha and clonally expanded T cells in the immunotherapy of chronic myelogenous leukemia. Leuk Lymphoma 2000, 38:21-38.
26. Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002, 20:3841-3849. 10.1200/JCO.2002.02.051, 12228203.
27. Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperativeadjuvant interferon therapy afterresection of hepatocellular carcinoma. Ann Surg 2007, 245:831-842. 10.1097/01.sla.0000245829.00977.45, 1876947, 17522506.
28. Clavien PA. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection?. Ann Surg 2007, 245:843-845. 10.1097/SLA.0b013e31805d0788, 1876968, 17522507.
29. Qian YB, Zhang JB, Wu WZ, et al. P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer 2006, 107:1562-1569. 10.1002/cncr.22206, 16948122.
30. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003, 314:15-23. 10.1007/s00441-003-0745-x, 12883993.
31. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose " chemo-switch" regimen is antiangiogenic, producing objective responses andsurvival benefit in amouse model of cancer. J Clin Oncol 2005, 23:939-952.
32. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth ofcells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997, 90:4947-4952.
33. Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 2001, 33:451-455. 10.3109/07853890109002093, 11680792.
34. Zhang T, Sun HC, Xu Y, et al. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 2005, 11:8557-8563. 10.1158/1078-0432.CCR-05-0944, 16361537.
35. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1-8. 10.1056/NEJM199101033240101, 1701519.
36. Deregibus MC, Cantaluppi V, Doublier S, et al. HIV-1-Tat protein activates phosphatidylinositol 3-kinase/ AKT-dependent survival pathways in Kaposi's sarcoma cells. J Biol Chem 2002, 277:25195-25202. 10.1074/jbc.M200921200, 11994280.
37. de Bont ES, Fidler V, Meeuwsen T, et al. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002, 8:2856-2861.
38. Poon RT, Lau CP, Cheung ST, et al. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003, 63:3121-3126.
39. Bieche I, Olivi M, Champeme MH, et al. Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer 1998, 78:661-666. 10.1002/(SICI)1097-0215(19981123)78:5<661::AID-IJC22>3.0.CO;2-I, 9808539.
40. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390:404-407. 10.1038/37126, 9389480.
41. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastaticcolorectal cancer. N Engl J Med 2004, 350:2335-2342. 10.1056/NEJMoa032691, 15175435.
42. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001, 61:5090-5101.
43. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309. 10.1016/j.ccr.2005.09.005, 16226705.
44. Kerbel RS. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 2005, 8:269-271. 10.1016/j.ccr.2005.09.016, 16226701.
45. Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005, 11:992-997.
46. Katano M, Nakamura M, Fujimoto K, et al. Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma. Ann Surg 1998, 227:365-371. 10.1097/00000658-199803000-00008, 1191274, 9527059.
47. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710. 10.1126/science.1079666, 12522257.